$5.05
-0.05[-0.98%]
At close: Apr 25
$5.05
0[0.00%]
PreMarket: 9:25AM EDT
Syros Pharmaceuticals
(NASDAQ:SYRS)Syros Pharmaceuticals Stock (NASDAQ:SYRS), Analyst Ratings, Price Targets, Predictions
Syros Pharmaceuticals Inc has a consensus price target of $14.83, established from looking at the 17 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, HC Wainwright & Co., and Piper Sandler on April 3, 2024, April 1, 2024, and October 3, 2023. With an average price target of $11.67 between Piper Sandler, HC Wainwright & Co., and Piper Sandler, there's an implied 131.02% upside for Syros Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
HC Wainwright & Co.
JMP Securities
Oppenheimer
Alliance Global Partners
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Syros Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/03/2024 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 157.43% | Piper Sandler | Edward Tenthoff | → $13 | Reiterates | Overweight → Overweight | Get Alert |
| 04/01/2024 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 197.03% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 10/03/2023 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 38.61% | Piper Sandler | Edward Tenthoff | $11 → $7 | Maintains | Overweight | Get Alert |
| 08/09/2023 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 197.03% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 197.03% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 197.03% | JMP Securities | Jason Butler | $16 → $15 | Maintains | Market Outperform | Get Alert |
| 03/03/2023 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 157.43% | Oppenheimer | Mark Breidenbach | $15 → $13 | Maintains | Outperform | Get Alert |
| 03/03/2023 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 197.03% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | → Buy | Get Alert |
| 01/05/2023 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 296.04% | Piper Sandler | Edward Tenthoff | $27 → $20 | Maintains | Overweight | Get Alert |
| 11/15/2022 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 216.83% | JMP Securities | Jason Butler | $40 → $16 | Maintains | Market Outperform | Get Alert |
| 11/15/2022 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 197.03% | Oppenheimer | Mark Breidenbach | $30 → $15 | Maintains | Outperform | Get Alert |
| 11/15/2022 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 296.04% | HC Wainwright & Co. | Andrew Fein | $6 → $20 | Maintains | Buy | Get Alert |
| 08/10/2022 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | -40.59% | Oppenheimer | Mark Breidenbach | $90 → $30 | Maintains | Outperform | Get Alert |
| 07/12/2022 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 18.81% | HC Wainwright & Co. | Andrew Fein | $100 → $60 | Maintains | Buy | Get Alert |
| 05/17/2022 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 98.02% | HC Wainwright & Co. | Andrew Fein | $150 → $100 | Maintains | Buy | Get Alert |
| 05/17/2022 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 98.02% | Alliance Global Partners | Matt Cross | $140 → $100 | Maintains | Buy | Get Alert |
| 09/23/2021 | SYRS | Buy Now | Syros Pharmaceuticals | $5.05 | 355.45% | Roth Capital | Zegbeh Jallah | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Syros Pharmaceuticals (SYRS)?
The latest price target for Syros Pharmaceuticals (NASDAQ: SYRS) was reported by Piper Sandler on April 3, 2024. The analyst firm set a price target for $13.00 expecting SYRS to rise to within 12 months (a possible 157.43% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Syros Pharmaceuticals (SYRS)?
The latest analyst rating for Syros Pharmaceuticals (NASDAQ: SYRS) was provided by Piper Sandler, and Syros Pharmaceuticals reiterated their overweight rating.
When was the last upgrade for Syros Pharmaceuticals (SYRS)?
There is no last upgrade for Syros Pharmaceuticals.
When was the last downgrade for Syros Pharmaceuticals (SYRS)?
There is no last downgrade for Syros Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Syros Pharmaceuticals (SYRS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syros Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syros Pharmaceuticals was filed on April 3, 2024 so you should expect the next rating to be made available sometime around April 3, 2025.
Is the Analyst Rating Syros Pharmaceuticals (SYRS) correct?
While ratings are subjective and will change, the latest Syros Pharmaceuticals (SYRS) rating was a reiterated with a price target of $0.00 to $13.00. The current price Syros Pharmaceuticals (SYRS) is trading at is $5.05, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.